Identification of HPV Integration and Genomic Patterns Delineating the Clinical Landscape of Cervical Cancer

  • Akeel, Raid-Al (Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University)
  • Published : 2016.01.11


Cervical cancer is one of the most common cancers in women worldwide. During their life time the vast majority of women become infected with human papillomavirus (HPV), but interestingly only a small portion develop cervical cancer and in the remainder infection regresses to a normal healthy state. Beyond HPV status, associated molecular characterization of disease has to be established. However, initial work suggests the existence of several different molecular classes, based on the biological features of differentially expressed genes in each subtype. This suggests that additional risk factors play an important role in the outcome of infection. Host genomic factors play an important role in the outcome of such complex or multifactor diseases such as cervical cancer and are also known to regulate the rate of disease progression. The aim of this review was to compile advances in the field of host genomics of HPV positive and negative cervical cancer and their association with clinical response.


Cervical cancer;HPV integration;genomic pattern


  1. Allie K Adams, Trisha M Wise-Draper, Susanne I (2014). Wells human papillomavirus induced transformation in cervical and head and neck cancers. Cancers (Basel), 6; 1793-820.
  2. Allen DG, White DJ, Hutchins AM, et al (2000). Progressive genetic aberrations detected by comparative genomic hybridization in squamous cell cervical cancer. Br J Cancer, 83, 1659-63.
  3. Argiris A, Karamouzis MV, Raben D, Ferris RL (2008). Head and neck cancer. Lancet, 371, 1695-709.
  4. Brady CA, Jiang D, Mello SS, et al (2011). Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell, 145, 571-583.
  5. Boren J, Brindle KM (2012). Apoptosis-induced mitochondrial dysfunction causes cytoplasmic lipid droplet formation. Cell Death Differ, 19, 1561-70.
  6. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA (2005). Eastern cooperative oncology g. phase iii randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study. J Clin Oncol, 23, 8646-54.
  7. Band V, De Caprio J, Delmolina L, Kulesa V, Sager R (1991). Loss of p53 protein in Human papillomavirus type 16 E6- immortalised human mammary epithelial cells. J Virol, 65, 6671-6.
  8. Behtash N, Mehrdad N (2006). Cervical cancer: screening and prevention. Asian Pac J Cancer Prev, 7, 683-6
  9. Bos JL (1989). ras oncogenes in human cancer: a review. Cancer Res, 49, 4682-9.
  10. Bardelli A, Siena S (2010). Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol, 28, 1254-61.
  11. Blumenschein GRJr, Glisson BS, Lu C, et al (2012). Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent SCCHN. J Clin Oncol, 30, 5592.
  12. Brockstein BE (2011). Management of recurrent head and neck cancer: recent progress and future directions. Drugs, 71, 1551-9.
  13. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, et al (2013). Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol, 31, 4550-9.
  14. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML (2008). Incidence trends for human papillamavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol, 26, 612-9.
  15. Dotto GP (2009). Crosstalk of notch with p53 and p63 in cancer growth control. Nat Rev Cancer, 9, 587-95.
  16. De Bacco F, Luraghi P, Medico E, et al (2011). Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst, 103, 645-61.
  17. Dayson N, Howley PM, Munger K, Harlow E (1989). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 243, 934-937.
  18. Egloff AM, Grandis JR (2012). Molecular pathways: contextdependent approaches to notch targeting as cancer therapy. Clin Cancer Res, 18, 5188-95.
  19. Engelman JA (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer, 9, 550-62.
  20. Hynes NE, Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 5, 341-354.
  21. Harrington K, Berrier A, Robinson M, et al (2013). Randomised phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer, 49, 1609-18.
  22. Janku F, Wheler JJ, Naing A, et al (2013). PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res, 73, 276-284.
  23. Keiko Akagi, Jingfeng Li, Tatevik R Broutian, et al (2014). Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res, 24, 185-99.
  24. Knowles LM, Stabile LP, Egloff AM, et al (2009). HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res, 15, 3740-50.
  25. Kibe R, Zhang S, Guo D, et al (2012). IL-7Ralpha deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis. Cell Death Differ, 19, 1139-51.
  26. Kolev V, Mandinova A, Guinea-Viniegra J, et al (2008). GFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol, 10, 902-11
  27. Krumbach R, Schuler J, Hofmann M, et al (2011). Primary resistance to cetuximab in a panel of patient-derived tumor xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer, 47, 1231-43.
  28. Leonova KI, Brodsky L, Lipchick B, et al (2013). p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci USA, 110, 89-98.
  29. Lo Muzio L, Farina A, Rubini C, et al (2006). Effect of c-Metexpression on survival in head and neck squamous cell carcinoma. Tumor Biol, 27, 115-121.
  30. Lando M, Holden M, Bergersen LC, et al (2009). Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet, 5, 1000719.
  31. Molinolo AA, Marsh C, El Dinali M, et al (2012). mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. Clin Cancer Res, 18, 2558-68.
  32. Morton JP, Timpson P, Karim SA, et al (2010). Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA, 107, 246-51
  33. Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC (2009). Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol, 92, 4-14.
  34. Qiu W, Schonleben F, Li X, et al (2006). PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res, 12, 1441-6.
  35. Seiwert TY, Jagadeeswaran R, Faoro L, et al (2009). The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res, 69, 3021-31.
  36. Sun S, Wang Z (2011). Head neck squamous cell carcinoma c-Met(+) cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer, 129, 2337-48.
  37. Seiwert T, Sarantopoulos J, Kallender H, et al (2013). Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs, 31, 417-24.
  38. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63, 1129-36.
  39. Talora C, Sgroi DC, Crum CP, Dotto GP (2002). Specific downmodulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev, 16, 2252-63.
  40. Ursula Winters, Richard Roden, Henry Kitchener, Peter Stern (2006). Progress in the development of a cervical cancer vaccine. Ther Clin Risk Manag, 2, 259-69.
  41. Vogelstein B, Lane D, Levine AJ (2000). Surfing the p53 network. Nature, 408, 307-310.
  42. Vermorken JB, Stohlmacher-Williams J, Davidenko I, et al (2013). Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an openlabel phase 3 randomised trial. Lancet Oncol, 14, 697-710.
  43. Walter V, Yin X, Wilkerson MD, et al (2013). Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonicalcancer genes. PLoS One, 8, 56823.
  44. Wilhelm SM, Adnane L, Newell P, et al (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther, 7, 3129-40.
  45. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-19.<12::AID-PATH431>3.0.CO;2-F
  46. zur Hausen H (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer, 2, 342-50
  47. Zhao D, Wang SH, Feng Y, et al (2011). Intratumoral c-Met expression is associated with vascular endothelial growth factor C expression, lymphangiogenesis, and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker. Hum Pathol, 42, 1514-23.